Drug Profile
ZPL 868087
Latest Information Update: 04 Apr 2017
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Ziarco
- Class
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-rhinitis in United Kingdom (PO)
- 05 Nov 2012 Preclinical trials in Allergic rhinitis in United Kingdom (PO)